British Journal of Dermatology · 2018 · 19 citations · 11 references
MedicineDermatologyOncologyChemotherapyCutaneous OncologyImmunotherapyCancer ImmunotherapyCutaneous LymphomaCutaneous NeoplasmsImmunopathology Of SkinInflammatory DermatosesLymphoid NeoplasmsAllogeneic Stem Cell InfusionAllogeneic Stem Cell TherapyComplete Response AssessmentCutaneous Immune-mediated DiseaseCutaneous T-cell Lymphoma TreatmentMonoclonal Antibody InfusionPsoriasiform DermatitisPsoriatic Disease
The erythrodermic ulcerated form of mycosis fungoides (MF) is exceptional, and treatment of refractory cases is challenging. Brentuximab vedotin (BV) is a monoclonal antibody combined with monomethyl auristatin E, recently approved for the treatment of refractory CD30+ cutaneous T‐cell lymphoma. We report a case of refractory MF in a 56‐year‐old man with a long history of large‐plaque parapsoriasis, as revealed by psoriasiform erythroderma, treated initially with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) polychemotherapy, inducing a 2‐year complete response. After relapse, interferon and gemcitabine were unsuccessful. Finally, treatment with BV was decided upon, despite the absence of CD30 expression. After three infusions of BV 1·8 mg kg−1, we achieved a complete and stable response, allowing an allogeneic stem cell transplant. The patient is still in complete remission, 19 months after the graft. This case illustrates the possibility of using BV in refractory CD30– MF as a salvage therapy.
11
Nita Agar, Emma Wedgeworth, Siobhan Crichton et al. · Journal of Clinical Oncology · 2010 · 845 citations
Medicine, Dermatology, Oncology +17
Long-term Outcome of 525 Patients With Mycosis Fungoides and Sézary Syndrome
Youn H. Kim, Howard L. Liu, Serena Mraz‐Gernhard et al. · Archives of Dermatology · 2003 · 652 citations
Medicine, Dermatology, Oncology +16